Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Patient harm from cardiovascular medications

View through CrossRef
Background Medication harm can lead to hospital admission, prolonged hospital stay and poor patient outcomes. Reducing medication harm is a priority for healthcare organisations worldwide. Recent Australian studies demonstrate cardiovascular (CV) medications are a leading cause of harm. However, they appear to receive less recognition as ‘high risk’ medications compared with those classified by the medication safety acronym, ‘APINCH’ (antimicrobials, potassium, insulin, narcotics, chemotherapeutics, heparin). Our aim was to determine the scale and type of medication harm caused by CV medications in healthcare. Methods A narrative review of adult (>16 years) medication harm literature identified from PubMed and CINAHL databases was undertaken. Studies with the primary outcome of measuring the incidence of medication harm were included. Harm caused by CV medications was described and ranked against other medication classes at four key stages of a patient’s healthcare journey. Where specified, the implicated medications and type of harm were investigated. Results A total of 75 studies were identified, including seven systematic reviews and three meta-analyses, with most focussing on harm causing hospital admission. CV medications were responsible for approximately 20% of medication harm; however, this proportion increased to 50% in older populations. CV medications were consistently ranked in the top five medication categories causing harm and were often listed as the leading cause. Conclusion CV medications are a leading cause of medication harm, particularly in older adults, and should be the focus of harm mitigation strategies. A practical approach to generate awareness among health professionals is to incorporate ‘C’ (for CV medications) into the ‘APINCH’ acronym. Plain language summary Patient harm from cardiovascular medications Background • Harm from medications can cause poor patient outcomes. • Certain medications have been identified as ‘high risk’ and are known to cause high rates of harm. • ‘High risk’ medications are included in medication guidelines used by health professionals. • Cardiovascular medications (e.g. blood pressure and cholesterol medications) are important and have many benefits. • Recent studies have found cardiovascular medications to cause high rates of harm. • Cardiovascular medication harm is often under-recognised in clinical practice. • Some guidelines do not consider cardiovascular medications to be ‘high risk’. Method • This review investigated the extent of harm caused by cardiovascular medications in adults across four healthcare settings: (1) at the time of hospital admission; (2) during hospital admission; (3) after hospital; and (4) readmission to hospital. • Harm caused by cardiovascular medications was ranked against other medication classes. • We investigated the type of cardiovascular medications to cause harm and the type of harm caused. Results • Seventy-five studies were reviewed across 41 countries. • Cardiovascular medications were ranked within the top five medications to cause harm. • Cardiovascular medications were a leading cause of harm in each healthcare setting investigated. • Harm caused by cardiovascular medications was common in older adults (>65 years). • Cardiovascular medications often caused preventable harm. • Medications to treat high blood pressure and abnormal heart rhythms were the most common causes of harm. • We reported kidney injury, electrolyte changes and low blood pressure as common types of harm. Conclusion • Increased focus on cardiovascular medications in clinical practice is needed. • Health professionals need to carefully prescribe and frequently review cardiovascular medications, especially in older adults. • Patient and health professional discussions should be based on both the benefits and harms of cardiovascular medications. • Cardiovascular medications should be included in all ‘high risk’ medication guidelines.
Title: Patient harm from cardiovascular medications
Description:
Background Medication harm can lead to hospital admission, prolonged hospital stay and poor patient outcomes.
Reducing medication harm is a priority for healthcare organisations worldwide.
Recent Australian studies demonstrate cardiovascular (CV) medications are a leading cause of harm.
However, they appear to receive less recognition as ‘high risk’ medications compared with those classified by the medication safety acronym, ‘APINCH’ (antimicrobials, potassium, insulin, narcotics, chemotherapeutics, heparin).
Our aim was to determine the scale and type of medication harm caused by CV medications in healthcare.
Methods A narrative review of adult (>16 years) medication harm literature identified from PubMed and CINAHL databases was undertaken.
Studies with the primary outcome of measuring the incidence of medication harm were included.
Harm caused by CV medications was described and ranked against other medication classes at four key stages of a patient’s healthcare journey.
Where specified, the implicated medications and type of harm were investigated.
Results A total of 75 studies were identified, including seven systematic reviews and three meta-analyses, with most focussing on harm causing hospital admission.
CV medications were responsible for approximately 20% of medication harm; however, this proportion increased to 50% in older populations.
CV medications were consistently ranked in the top five medication categories causing harm and were often listed as the leading cause.
Conclusion CV medications are a leading cause of medication harm, particularly in older adults, and should be the focus of harm mitigation strategies.
A practical approach to generate awareness among health professionals is to incorporate ‘C’ (for CV medications) into the ‘APINCH’ acronym.
Plain language summary Patient harm from cardiovascular medications Background • Harm from medications can cause poor patient outcomes.
• Certain medications have been identified as ‘high risk’ and are known to cause high rates of harm.
• ‘High risk’ medications are included in medication guidelines used by health professionals.
• Cardiovascular medications (e.
g.
blood pressure and cholesterol medications) are important and have many benefits.
• Recent studies have found cardiovascular medications to cause high rates of harm.
• Cardiovascular medication harm is often under-recognised in clinical practice.
• Some guidelines do not consider cardiovascular medications to be ‘high risk’.
Method • This review investigated the extent of harm caused by cardiovascular medications in adults across four healthcare settings: (1) at the time of hospital admission; (2) during hospital admission; (3) after hospital; and (4) readmission to hospital.
• Harm caused by cardiovascular medications was ranked against other medication classes.
• We investigated the type of cardiovascular medications to cause harm and the type of harm caused.
Results • Seventy-five studies were reviewed across 41 countries.
• Cardiovascular medications were ranked within the top five medications to cause harm.
• Cardiovascular medications were a leading cause of harm in each healthcare setting investigated.
• Harm caused by cardiovascular medications was common in older adults (>65 years).
• Cardiovascular medications often caused preventable harm.
• Medications to treat high blood pressure and abnormal heart rhythms were the most common causes of harm.
• We reported kidney injury, electrolyte changes and low blood pressure as common types of harm.
Conclusion • Increased focus on cardiovascular medications in clinical practice is needed.
• Health professionals need to carefully prescribe and frequently review cardiovascular medications, especially in older adults.
• Patient and health professional discussions should be based on both the benefits and harms of cardiovascular medications.
• Cardiovascular medications should be included in all ‘high risk’ medication guidelines.

Related Results

Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash Abstract This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Preventable medication harm across health care settings: a systematic review and meta-analysis
Preventable medication harm across health care settings: a systematic review and meta-analysis
Abstract Background Mitigating or reducing the risk of medication harm is a global policy priority. But evidence reflecting preventab...
A Scoping Review: Self-harm pada Remaja
A Scoping Review: Self-harm pada Remaja
Abstract. Adolescents are seen as an age group that is vulnerable to self-harm. In recent years, cases of self-harm have increased. Exposure to physical, emotional, social changes ...
Doing and Allowing
Doing and Allowing
AbstractIs there a morally significant distinction between doing and allowing? The most natural way to understand this question is as asking whether doing harm is worse, in itself,...
Unplanned Rehospitalisation due to Medication Harm following an Acute Myocardial Infarction
Unplanned Rehospitalisation due to Medication Harm following an Acute Myocardial Infarction
<b><i>Introduction:</i></b> The contribution of medication harm to rehospitalisation and adverse patient outcomes after an acute myocardial infarction (AMI)...
Early maladaptive schemas are associated with self-injury thoughts and behavior in adolescents
Early maladaptive schemas are associated with self-injury thoughts and behavior in adolescents
Abstract Background Early maladaptive schemas (EMSs) and self-harm have been firmly linked in adults, but research on these associations in adolesce...

Back to Top